FDA Approves Effective Topical Foam for Treating Scalp and Body Plaque Psoriasis
The FDA has approved Zoryve foam, a steroid-free topical treatment for scalp and body plaque psoriasis in adolescents and adults, backed by clinical trial success in clearing psoriasis and relieving itching.
The U.S. Food and Drug Administration (FDA) has granted approval for Zoryve (roflumilast) topical foam 0.3% developed by Arcutis Biotherapeutics, specifically for managing plaque psoriasis affecting the scalp and body. This medication is suitable for adults and adolescents aged 12 years and older. Notably, Zoryve is a steroid-free, once-daily treatment option, offering a convenient approach for patients.
The approval followed positive results from comprehensive clinical trials, including the Phase III ARRECTOR trial and a Phase II trial (Trial 204). In these studies, a total of 736 participants with mild to severe plaque psoriasis on the scalp and body were randomized to apply either Zoryve foam or a placebo foam daily over an eight-week period. The efficacy was assessed using the Investigator Global Assessment (IGA) scale.
Results demonstrated significant improvement, with 66.4% of patients in the ARRECTOR trial achieving success on the Scalp-IGA at week eight, compared to 27.8% treated with placebo. Similarly, 45.5% achieved Body-IGA success versus 20.1% on placebo. The Phase II trial echoed these findings, with 56.7% of patients reaching Scalp-IGA success and 39.0% achieving Body-IGA success.
According to Jennifer Soung, M.D., clinical director at Southern California Dermatology, Zoryve foam not only effectively clears psoriasis plaques but also provides rapid itch relief. Its safety profile supports indefinite use, and its two formulations, cream and foam, offer healthcare providers flexible treatment options.
This approval marks a significant advancement in psoriasis therapy, particularly as it allows for comprehensive management of scalp and body psoriasis with a single prescription, transforming the treatment landscape for patients with this chronic condition.
source: https://medicalxpress.com/news/2025-05-fda-topical-foam-plaque-psoriasis.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Limited Access to Alzheimer's Treatments in Rural Georgia Raises Concerns
A new study reveals significant disparities in Alzheimer's treatment access for rural residents in Georgia, highlighting urgent healthcare inequities and the need for resource redistribution.
Understanding the Differences Between Sperm and Semen: Can Pre-Ejaculate Lead to Pregnancy?
Learn about the key differences between sperm and semen, the role of pre-ejaculate, and how these factors influence male fertility and pregnancy risks.
How Hearing Loss and Loneliness Speed Up Cognitive Decline in Older Adults
New research shows that hearing impairment combined with loneliness can significantly speed up cognitive decline in seniors, emphasizing the importance of early hearing care and emotional support.
Breakthrough in Primate Stem Cell Research: Adult Cells Identified in Small Non-Human Primate
Scientists have uncovered adult stem cells in a small non-human primate, the mouse lemur, offering promising new avenues for regenerative medicine and muscle disease treatments. This discovery enhances our understanding of primate biology and improves the development of human therapies.